How vast is the public healthcare challenge of Cancer?
Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly 1 in 6 total deaths.1 Low-and-middle-income countries shoulder most of the cancer burden, accounting for a staggering 70% of the cancer deaths in 2020.1 The most common cancers are breast, lung, colon/rectum, and prostate.
According to estimates from the International Agency for Research on Cancer (IARC), by 2040, the global burden is expected to grow to
27.5 million new cancer cases and 16.3 million cancer deaths simply due to the growth and aging of the population.2 The future burden may even be larger due to factors such as smoking, unhealthy diet, and physical inactivity that continue to increase in prevalence.
The continued growth of the cancer impact imposes significant economic challenges on our healthcare systems. The costs associated with cancer diagnosis, treatment, and long-term care can be substantial. Many health systems in low- and middle-income countries are least prepared to manage this burden, and large numbers of cancer patients globally do not have access to timely quality diagnosis and treatment.3
What is the role of bioMérieux Cancer diagnostics?
bioMérieux provides diagnostic tools needed for both early and accurate detection and to guide appropriate and quality treatment. To make the best possible decision for patients, physicians must first identify the type of cancer they need to manage and treat. Our tests help clinicians estimate prognosis with a high degree of accuracy and adapt their treatment strategy accordingly, whether the patient needs surgery, radiation therapy, chemotherapy, or another type of treatment. The care patients receive depends on the progression of the disease which is why accurate assessment of the cancer is absolutely critical.
Early evaluation of a patient’s response to the selected treatment is also important. Our diagnostic tests support clinicians in evaluating therapy efficacy.
Cancer - Our Diagnostic Offer
This immunoassay platform offers several tests for the measurement of tumor markers of breast, colorectal, prostate, liver, ovary, and pancreatic cancers.
Disclaimer: Product availability varies by country. Please consult your local bioMérieux representative for product availability in your country.
Trusted. Robust. Innovative.
With its advanced immunoassay technology and optimized testing protocols, the fully automated VIDAS® 3 benchtop immunoanalyzer empowers your lab with confidence, offering the precise results you need, when you need them.
Stackable benchtop automated immunoassay solution
VIDAS® KUBE™ is designed to preserve everything labs appreciate about the VIDAS® Solution combined with advanced technology. VIDAS® KUBE™ is a truly flexible, cost-effective automated immunoassay solution providing fast results in complete confidence.
Contact Us About Our Diagnostic Solutions For Cancer
1. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, et al. Global Cancer Observatory: Cancer Today. Lyon: International Agency for Research on Cancer; 2020 https://gco.iarc.fr/today.
2. WHO (2017) Obesity and overweight Fact sheet. Available from: https://www.who.int/en/news-room/fact-sheets/detail/obesity-and-overweight.
3. WHO (2023) Cancer. Available from: https://www.who.int/health-topics/cancer#tab=tab_1.